SRRK
$40.71
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
Intraday
Recent News
Scholar Rock Holding Corporation Q4 2025 Earnings Call Summary
Moby summary of Scholar Rock Holding Corporation's Q4 2025 earnings call
Scholar Rock Q4 Earnings Call Highlights
Scholar Rock (NASDAQ:SRRK) executives said the company is “poised for a transformative year in 2026,” with its top priority centered on resubmitting the biologics license application (BLA) for apitegromab in spinal muscular atrophy (SMA) after an FDA reinspection of the Catalent Indiana fill-finish
Assessing Scholar Rock (SRRK) Valuation After Recent Share Pullback And Conflicting P/B And DCF Signals
With no single headline event driving attention today, Scholar Rock Holding (SRRK) is back on watch for many investors as they reassess recent share performance, clinical focus, and the company’s current financial profile. See our latest analysis for Scholar Rock Holding. Scholar Rock Holding’s share price has pulled back 2.06% over the last day to US$47.01. The 30 day share price return of 6.14% and one year total shareholder return of 26.51% sit within a much stronger three year total...
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.